Theravance Biopharma, Inc. — Form 8-K
Filed August 25, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
The CYPRESS Phase 3 trial of ampreloxetine for neurogenic orthostatic hypotension failed its primary endpoint—change in OHSA composite score at week 8 (randomized withdrawal period) was not statistically significant. Post hoc analyses of a refined 'confirmed symptomatic nOH' subpopulation (n=47) showed numerical improvements (p=0.001 for average OHSA, OHDAS, OHQ over weeks 2–8), but the pivotal trial did not succeed as designed. FDA indicated in May 2026 Type B meeting that approval is not supported by current data; however, the agency indicated an additional pivotal trial could offer a path forward. Theravance held a Type C meeting in July 2026 to discuss future study design.
Why this rating
Failed Phase 3 primary endpoint is major setback for lead candidate in $448M company; post hoc subgroup results and FDA willingness to discuss future trial prevent complete program collapse, but pivotal failure is trajectory-altering.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.